fibronostics logo bw

Is A First-Line NASH Diagnostic Test

A Rapidly Growing Burden Of NAFLD/NASH

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25%, and its burden continues to increase in parallel with the obesity epidemic and lack of systematic screening. NAFLD and NASH (Non-alcoholic steatohepatitis) are the hepatic manifestations of metabolic syndrome (MetS).

NASH is an asymptomatic progressive form of NAFLD that can lead to cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation. The incidence of HCC is increasing by 3% per year due to obesity.

NASH is anticipated to become the primary indication for liver transplantation due to the combination of increasing obesity prevalence worldwide, the lack of noninvasive screening tests, and approved therapies.​​

Problems For Identifying NASH

  • The lack of awareness, symptoms, and systematic screening makes NASH underdiagnosed.
  • Liver biopsy remains the gold standard indication to diagnose NASH, despite limitations:
    • Risks: 3/1000 complications and 3/10000 mortality rate.
    • Sampling variability and biases between pathologists.
    • Unsustainable to monitor the progression or regression of NASH.
    • Not practical for large scale screening.

LIVERFASt™ Helps Physicians And Patients In Fighting NASH

The only noninvasive blood test that can effectively stratify NAFLD and NASH, and provide guidance for the clinical management of patients.

Fibronostics Diagnosis

Simple Scorings

LIVERFASt™ provides scoring and staging for the three lesions of NAFLD/NASH (fibrosis, activity, and steatosis).

Fibronostics Screening

NAFLD Stratification

LIVERFASt™ stratifies the severity of NASH and provides granularity to monitor each liver lesion.

Fibronostics Monitoring

Noninvasive Test

A widely available blood-based surrogate of liver biopsy that provides a complete liver assessment for NASH.

LIVERFASt™ Has Similar Accuracy To Transient Elastography
For Cirrhosis Diagnosis But With Better Applicability

Support International NASH Day


  • Chalassani N, et al. Hepatology. 2018 Jan;67:328-357.
  • Younossi ZM, et al. Hepatology. 2016;64:73–84.
  • Aravind A, et al. JILSA. 2020;12:31-49.
  • De Lédinghen V, et al. Hepatology 2020.72;1:906A
  • Raskin M, et al. Hepatology 2020.72;1:273A
  • Cohn B, et al. Hepatology 2020.72;1:943A
  • De Ledinghen V, et al. J Hepatol 2021:#198 (abstract)
  • Ratziu V, et al. 2005 Jun;128:1898-906.
  • Diehl AM, et al. NEJM. 2017; 377: 2063-2072.
  • Wong RJ, et al. Gastroenterology. 2015;148: 547-55.